Antibiotic Therapy for Intraabdominal Infections

Introduction to Antibiotic Selection

Piperacilina/Tazobactam provides excellent coverage against anaerobes, including Bacteroides fragilis, and maintains activity in vitro against Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBL) and some strains producing carbapenemases, with higher activity against OXA-48 and KPC strains, as recommended by the American College of Surgeons 1, 2
The World Health Organization and the Infectious Diseases Society of America (IDSA) recommend cefotaxime or ceftriaxone combined with metronidazole as the preferred cephalosporin-based regimen for outpatient treatment of infectious colitis, providing adequate coverage against common enteric pathogens and anaerobic organisms 3, 4

Piperacilina/Tazobactam is preferred for intraabdominal infections where anaerobes are significant pathogens, and as an alternative to carbapenems to reduce the selection of carbapenemase-producing strains, due to its broad coverage and activity against ESBL-producing strains 1
It is a valuable option for polymicrobial infections caused by aerobic and anaerobic bacteria producing beta-lactamases, and can be a strategy to avoid carbapenem use in settings with high resistance prevalence, as recommended by the IDSA 1, 5

Cefepime has limited activity against anaerobic bacteria and requires the addition of metronidazole when anaerobes are likely pathogens, whereas Piperacilina/Tazobactam provides broad coverage against anaerobes 1
Cefepime is recommended when anaerobic coverage is not required or metronidazole will be added, or when Pseudomonas aeruginosa with derepressed AmpC is suspected, as noted by the IDSA 5

Prefer Piperacilina/Tazobactam when suspected infection involves anaerobes, or when coverage against ESBL-producing strains is needed without carbapenem use, and in complex polymicrobial infections, as recommended by the IDSA and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 1, 3, 6
Prefer Cefepime when anaerobic coverage is not required or metronidazole will be added, or when Pseudomonas aeruginosa with derepressed AmpC is suspected, as noted by the IDSA 5
The IDSA recommends adding anaerobic coverage, such as metronidazole, when using cephalosporins for intra-abdominal infections, including infectious colitis, due to limited activity against anaerobes 4, 5

For mild-to-moderate community-acquired infectious colitis, the recommended treatment is oral ceftriaxone (if available in oral form) or parenteral ceftriaxone with transition to oral therapy + metronidazole, as suggested by the Clinical Microbiology and Infection guidelines 3, 7
Alternative treatment for mild-to-moderate community-acquired infectious colitis is ciprofloxacin + metronidazole, although this is considered a second choice due to resistance concerns, according to the Clinical Microbiology and Infection guidelines 3
For severe infectious colitis, the recommended treatment is cefotaxime or ceftriaxone + metronidazole, with alternative options including piperacillin-tazobactam or meropenem, as recommended by the Clinical Microbiology and Infection guidelines and the ESCMID 3, 6
Piperacillin-tazobactam, carbapenems (such as imipenem, meropenem, and ertapenem), and ampicillin-sulbactam are recommended for infections where anaerobes are important pathogens due to their broad spectrum of activity against both aerobic and anaerobic bacteria, as noted by the IDSA and the ESCMID 5, 8, 6

Ceftriaxone + metronidazole allows for once-daily dosing due to its long half-life, making it convenient for outpatient management, as noted in the Clinical Infectious Diseases journal 4, 3
The risk of C. difficile infection is associated with cephalosporin use, and monitoring for new or worsening diarrhea during treatment is recommended, with consideration of C. difficile testing if diarrhea persists or worsens, as recommended by the IDSA and the ESCMID 6, 9
For patients with penicillin allergy, cephalosporins may still be used if there is no history of anaphylaxis, and alternative treatments such as ciprofloxacin + metronidazole may be considered for severe penicillin allergy, as recommended by the Clinical Infectious Diseases journal 7
For patients with renal impairment, dosing adjustments of ceftriaxone or cefotaxime according to creatinine clearance are necessary, although the specific recommendation is not provided in the given citations

The duration of therapy for uncomplicated cases of infectious colitis is typically 7-10 days, as suggested by the Clinical Infectious Diseases journal 7
Assessment of response after 3 days of treatment, including decreased stool frequency and improved consistency, is recommended, according to the Clinical Microbiology and Infection guidelines 10
Follow-up evaluation for resolution of symptoms and consideration of transition to oral therapy when clinical improvement occurs is recommended, as noted in the Clinical Infectious Diseases journal 7
Evaluate the severity of the infection, including the presence of sepsis or septic shock, infection location, and patient comorbidities, and initiate carbapenem treatment (imipenem or meropenem) for severe infections or bacteremia, with consideration of sequential oral therapy according to the antibiogram if clinical improvement occurs, as recommended by the ESCMID 6